A new study appearing in the current edition of the Journal of Occupational and Environmental Medicine may provide plaintiffs in talc litigation the most powerful evidence yet discovered linking asbestos-contaminated talcum powder to mesothelioma.
How much did Johnson & Johnson really know about asbestos contamination of the talc it used in its Baby Powder? A federal grand jury has been impaneled by the US Department of Justice (DoJ) to find an answer to just that question.
A group of 22 women suffering from ovarian cancer caused by asbestos-containing talcum powder were vindicated this week when a St. Louis jury ordered health care products manufacturer Johnson & Johnson to pay nearly $4.7 billion in damages.
Jury Finds Johnson & Johnson, Imerys Liable in Lawsuit Claiming Talcum Powder Caused Mesothelioma Cancer
In a stunning verdict handed down in a federal court in New Jersey, a jury has ordered pharmaceutical giant Johnson & Johnson and its talc supplier, Imerys, to pay $37 million to a 46-year-old man who alleged that his mesothelioma was caused by his regular use of the defendant's talc-containing products over the course of his lifetime. The trial, which ended yesterday, is the most recent bellwether case over allegations that Johnson & Johnson's flagship products, Baby Powder and Shower to Shower, are carcinogenic.
In August, a Los Angeles jury ordered Johnson & Johnson to pay $417 million to 63-year-old Eva Echeverria, a woman who is now in the terminal stage of ovarian cancer due to having used the company's talc-containing Baby Powder since puberty.
Johnson & Johnson Loses Big in Latest Talcum Powder Ovarian Cancer Verdict: Jury Awards $415 Million
This week, Johnson & Johnson was ordered to pay $415 million to a California woman who alleged that her ovarian cancer was caused by the company's talc-containing Baby Powder. Eva Echeverria, now hospitalized and in the final stages of her illness, said she used the product daily for most of her life. She was diagnosed with ovarian cancer in 2007.
Pharmaceutical Industry Lobbyist Requests to be Removed From List of Defendants in Talcum Powder Trials
Defendants in current trials over the link between talcum powder and ovarian cancer include Johnson & Johnson, manufacturer of the most popular baby powder, and Imerys Talc America, supplier of the talc used in the product. However, there has been a third named defendant: the Personal Care Products Council (PCPC). Based in Washington D.C., the PCPC is a trade association and lobbying group, representing over 600 companies that manufacture and distribute personal care products.
Johnson & Johnson Presents “4 Important Facts About the Safety of Talc” – But Are They Really Factual?
As the number of lawsuits over talc-containing Baby Powder continues to grow, manufacturer Johnson & Johnson – once “The Most Trusted Brand in America” – has been fighting back in order to convince the public of the safety of their product. To that end, the J&J corporate website now has a page on “4 Important Facts About the Safety of Talc.” But is the information accurate? What are the facts?
Recent news about the talc included in Johnson & Johnson's Baby Powder and its links to ovarian cancer has many women greatly concerned – and rightfully so. Although juries have been finding for the plaintiffs in a number of cases, awarding judgments in the tens of millions of dollars, the New Jersey-based pharmaceutical giant continues to assert that its product is “safe” and there is no proof that talcum powder causes ovarian cancer.
At the end of October, a jury in St. Louis, Missouri, awarded $67.5 million to a plaintiff who stated her ovarian cancer was the result of using Johnson & Johnson Baby Powder – a product containing talc. This is the third loss in a row for the pharmaceutical and health care products company. All three trials were held in a state court in St. Louis. So far, J&J’s total liability amounts to approximately $195 million. Although such awards are often reduced and sometimes even overturned on appeal, the prospects aren't looking good for the defendants.